You need JavaScript to view this

Parenteral administration of GM1 ganglioside to presenile Alzheimer patients

Journal Article:

Abstract

The pharmacokinetic parameters of GM1 ganglioside were examined in 16 patients (mean age 64 {plus minus} 5 years) with Alzheimer's disease. The ganglioside was given intramuscularly and subcutaneously. The maximum GM1 blood level was reached after 48-72 h, the subcutaneous route leading to the highest blood levels, but the individual variability was relatively large. When 100 mg GM1 ganglioside was given daily for a week, maximum serum values of 15 to 20 {sup m}u{sup m}ol/l were found in 3 patients. The elimination half-life from serum was 60-75 h. (author).
Authors:
Svennerholm, L; Gottfries, C G; Blennow, K; Fredman, P; Karlsson, I; Maansson, J -E; [1]  Toffano, G; Wallin, A [2] 
  1. Department of Psychiatry and Neurochemistry, Gothenburg University (Sweden)
  2. Fidia Research Laboratories, Abano Terme (Italy)
Publication Date:
Jan 01, 1990
Product Type:
Journal Article
Reference Number:
AIX-21-058304; EDB-90-112852
Resource Relation:
Journal Name: Acta Neurologica Scandinavica; (Denmark); Journal Volume: 81
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; 38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; ELDERLY PEOPLE; MENTAL DISORDERS; GANGLIOSIDES; BRAIN; BOROHYDRIDES; INTRAMUSCULAR INJECTION; LABELLING; TRITIUM COMPOUNDS; AGE GROUPS; AGED ADULTS; BODY; BORON COMPOUNDS; CARBOHYDRATES; CENTRAL NERVOUS SYSTEM; GLYCOLIPIDS; HUMAN POPULATIONS; HYDROGEN COMPOUNDS; INJECTION; INTAKE; LIPIDS; MINORITY GROUPS; NERVOUS SYSTEM; ORGANIC COMPOUNDS; ORGANS; POPULATIONS; SACCHARIDES; 560161* - Radionuclide Effects, Kinetics, & Toxicology- Man; 400703 - Radiochemistry & Nuclear Chemistry- Radioisotope Production
OSTI ID:
7043052
Country of Origin:
Denmark
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0001-6314; CODEN: ANRSA
Submitting Site:
DKN
Size:
Pages: 81
Announcement Date:

Journal Article:

Citation Formats

Svennerholm, L, Gottfries, C G, Blennow, K, Fredman, P, Karlsson, I, Maansson, J -E, Toffano, G, and Wallin, A. Parenteral administration of GM1 ganglioside to presenile Alzheimer patients. Denmark: N. p., 1990. Web.
Svennerholm, L, Gottfries, C G, Blennow, K, Fredman, P, Karlsson, I, Maansson, J -E, Toffano, G, & Wallin, A. Parenteral administration of GM1 ganglioside to presenile Alzheimer patients. Denmark.
Svennerholm, L, Gottfries, C G, Blennow, K, Fredman, P, Karlsson, I, Maansson, J -E, Toffano, G, and Wallin, A. 1990. "Parenteral administration of GM1 ganglioside to presenile Alzheimer patients." Denmark.
@misc{etde_7043052,
title = {Parenteral administration of GM1 ganglioside to presenile Alzheimer patients}
author = {Svennerholm, L, Gottfries, C G, Blennow, K, Fredman, P, Karlsson, I, Maansson, J -E, Toffano, G, and Wallin, A}
abstractNote = {The pharmacokinetic parameters of GM1 ganglioside were examined in 16 patients (mean age 64 {plus minus} 5 years) with Alzheimer's disease. The ganglioside was given intramuscularly and subcutaneously. The maximum GM1 blood level was reached after 48-72 h, the subcutaneous route leading to the highest blood levels, but the individual variability was relatively large. When 100 mg GM1 ganglioside was given daily for a week, maximum serum values of 15 to 20 {sup m}u{sup m}ol/l were found in 3 patients. The elimination half-life from serum was 60-75 h. (author).}
journal = {Acta Neurologica Scandinavica; (Denmark)}
volume = {81}
journal type = {AC}
place = {Denmark}
year = {1990}
month = {Jan}
}